Literature DB >> 6170342

Studies on the synthesis and degradation of a high molecular weight, histidine-rich phosphoprotein from mammalian epidermis.

I R Scott, C R Harding.   

Abstract

The synthesis and subsequent fate of the histidine-rich proteins, which form a major component of keratohyalin granules in mammalian epidermis, have been studied in the guinea-pig and new-born rat. In both species the protein first synthesised is of very high molecular weight, approximately 340 000. It is short-lived and breaks down to lower molecular weight proteins 1-2 days after its synthesis. These smaller proteins differ in the two species. In the guinea-pig, the high molecular weight protein breaks down to proteins of molecular weight 250 000 and 200 000, which are themselves unstable and break down to low molecular weight species, probably amino acids. The initial breakdown of the high molecular weight protein coincides with the dispersion of the keratohyalin granules and the transition of the granular cell into the stratum corneum. This high molecular weight histidine-rich protein has been purified to homogeneity, despite its instability to several treatments during purification. The protein is highly phosphorylated, containing 6 mol% of phosphoserine, but is otherwise very basic. The possibility that dephosphorylation of the protein produces highly basic matrix proteins in the stratum corneum is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6170342     DOI: 10.1016/0005-2795(81)90224-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  18 in total

1.  Immunofluorescence localization of the epidermolytic toxin target in mouse epidermal cells and tissue.

Authors:  B P Lockhart; T P Smith; C J Bailey
Journal:  Histochem J       Date:  1991-09

2.  Decreased expression of filaggrin in atopic skin.

Authors:  T Seguchi; C Y Cui; S Kusuda; M Takahashi; K Aisu; T Tezuka
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

3.  Candidacidal activities of proteins partially purified from rat epidermis.

Authors:  M Kashima; H Takahashi; M Shimozuma; W L Epstein; K Fukuyama
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

4.  Normal human epidermal keratinocytes express in vitro specific molecular forms of (pro)filaggrin recognized by rheumatoid arthritis-associated antifilaggrin autoantibodies.

Authors:  E Girbal-Neuhauser; M Montézin; F Croute; M Sebbag; M Simon; J J Durieux; G Serre
Journal:  Mol Med       Date:  1997-02       Impact factor: 6.354

5.  The binding of epidermolytic toxin from Staphylococcus aureus to mouse epidermal tissue.

Authors:  T P Smith; D A John; C J Bailey
Journal:  Histochem J       Date:  1987-03

6.  Effects of filaggrin breakdown products on the growth and maturation of keratinocytes.

Authors:  J Mansbridge; M Knapp
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

7.  Evidence for filaggrin as a component of the cell envelope of the newborn rat.

Authors:  S Richards; I R Scott; C R Harding; J E Liddell; G M Powell; C G Curtis
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

8.  Epidermal proteins. I. Differential extraction and quantitative polyacrylamide gel-electrophoretic analysis of basal spinous-cell proteins of neonatal mouse epidermis.

Authors:  R S Labib; G J Anhalt; H P Patel; L A Diaz
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

9.  Kallikrein-related peptidase 5 functions in proteolytic processing of profilaggrin in cultured human keratinocytes.

Authors:  Jun-ichi Sakabe; Mami Yamamoto; Satoshi Hirakawa; Akira Motoyama; Isao Ohta; Kazuki Tatsuno; Taisuke Ito; Kenji Kabashima; Toshihiko Hibino; Yoshiki Tokura
Journal:  J Biol Chem       Date:  2013-04-29       Impact factor: 5.157

10.  Immunohistochemical detection of filaggrin in preneoplastic and neoplastic lesions of the human oral mucosa.

Authors:  M E Itoiz; C J Conti; H E Lanfranchi; M Mamrack; A J Klein-Szanto
Journal:  Am J Pathol       Date:  1985-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.